首页> 美国卫生研究院文献>other >Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers
【2h】

Determining P-glycoprotein-drug interactions: evaluation of reconstituted P-glycoprotein in a liposomal system and LLC-MDR1 polarized cell monolayers

机译:测定p-糖蛋白 - 药物相互作用:对脂质体体系中重构的p-糖蛋白的评价和LLC-MDR1偏振细胞单层

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionP-Glycoprotein (ABCB1, MDR1) is a multidrug efflux pump that is a member of the ATP-binding cassette (ABC) superfamily. Many drugs in common clinical use are either substrates or inhibitors of this transporter. Quantitative details of P-glycoprotein inhibition by pharmaceutical agents are essential for assessment of their pharmacokinetic behavior and prevention of negative patient reactions. Cell-based systems have been widely used for determination of drug interactions with P-glycoprotein, but they suffer from several disadvantages, and results are often widely variable between laboratories. We aimed to demonstrate that a novel liposomal system employing contemporary biochemical methodologies could measure the ability of clinically used drugs to inhibit the P-glycoprotein pump. To accomplish this we compared results with those of cell-based approaches.
机译:介绍 - 糖蛋白(ABCB1,MDR1)是多药中泵,其是ATP结合盒(ABC)超家族的成员。常见临床用途的许多药物是该转运蛋白的底物或抑制剂。药物对p-糖蛋白抑制的定量细节对于评估其药代动力学行为和预防负患者反应至关重要。基于细胞的系统已被广泛用于测定与p-糖蛋白的药物相互作用,但它们遭受若干缺点,并且在实验室之间往往是广泛的可变的。我们的旨在证明,采用当代生化方法的新型脂质体系统可以测量临床使用的药物抑制p-糖蛋白泵的能力。为了实现这一点,我们将结果与基于细胞的方法进行了比较。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号